Clinical Trials

Papers
(The H4-Index of Clinical Trials is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials54
Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry44
A critique on “A randomized evaluation of on-site monitoring nested in a multinational randomized trial”31
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials27
Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial26
Rethinking intercurrent events in defining estimands for tuberculosis trials26
Effects of patient-reported outcome assessment order25
Random effect misspecification in stepped wedge designs25
A review of current practice in the design and analysis of extremely small stepped-wedge cluster randomized trials23
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges23
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials20
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials20
Partner engagement for planning and development of non-pharmacological care pathways in the AIM-Back trial19
How is missing data handled in cluster randomized controlled trials? A review of trials published in the NIHR Journals Library 1997–202418
Characterization of studies considered and required under Medicare’s coverage with evidence development program17
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience16
Training the next generation of clinical trial biostatisticians16
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies16
Influential methods reports for group-randomized trials and related designs16
0.064748048782349